ClinicalTrials.Veeva

Menu

Tobacco Cessation Among Smokers Under Alcohol and/or Cannabis Treatment (ACT-ATAC)

I

Institut Català d'Oncologia

Status

Unknown

Conditions

Mental Health Disorder
Cannabis Use
Alcohol Abuse
Substance Abuse Drug
Smoking Cessation
Tobacco Use

Study type

Observational

Funder types

Other

Identifiers

NCT04841655
PI18/01420

Details and patient eligibility

About

Aims: To identify the predictors associated with smoking cessation in smokers under treatment for alcohol and/or cannabis treated in drug treatment centers (DTC). Methodology: Mixed methods project with qualitative and quantitative designs (three studies). Study I discussion groups: of clinical professionals of DTC to explore the barriers/facilitators of these smokers in quitting and the interventions carried out. Study II Prospective cohort of smokers in alcohol and/or cannabis treatment that will be followed-up for 12 months. Sample size: difference in incidence (exposed to cessation interventions versus non-exposed = 12 per 100 years), α = 0.05, β = 0.10, losses = 20% (n = 726). Dependent variables: self-reported and verified tobacco consumption abstinence, quit attempts, motivation, and self-efficacy. Independent variables: age, sex, the substance under treatment. Analysis: incidence, relative risk and simple and multiple logistic regression models (odds ratio and confidence interval, CI, 95%) of quitting. Study III discussion groups: with smokers under alcohol and/or cannabis treatment selected according to their typology. Analysis: of thematic content and triangulation qualitative and quantitative results. Expected results: Characterization of variables that influence tobacco cessation, to improve the design of interventions.

Enrollment

1,625 estimated patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Smokers (at least 1cig./week)
  • Undertreatment for Cannabis and/or Alcohol Abuse for the first time
  • >=18 years-old
  • Under clinical follow-up
  • Informed consent

Exclusion criteria

  • Severe cognitive impairment
  • 12-month follow-up not guaranteed

Trial contacts and locations

2

Loading...

Central trial contact

Ariadna Feliu Josa, MPH; Cristina Martinez Martinez, PhD

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems